Adamas Pharma (ADMS): ADS-5102 Pricing Could Be Higher Than Expected, Raising PT - Mizuho
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mizuho Securities analyst, Irina Koffler. reiterated her Buy rating Adamas Pharmaceuticals (NASDAQ: ADMS) and raised her price target to $26 from $22 after a recent deal in the Parkinson's space indicates pricing for ADS-5102 could be higher than expected.
The next event for the company is the ADS-5102 NDA submission in late 2016.
Shares of Adamas Pharmaceuticals closed at $15.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Target (TGT) PT, Estimates Cut at Buckingham Research Following Miss
- BTIG Raises Price Target on CardConnect Corp. (CCN) to $17; Reiterates Buy
- UBS Boosts PT On NRG Energy (NRG) Citing Evidence Of "A Bit Of A Turn Around"
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!